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We have found that ecteinascidin-743 (ET-743) inhib-
ited cell proliferation at 1–10 ng/ml, leading to S and
G2/M arrest and subsequent apoptosis, and induced
early apoptosis without previous cell cycle arrest at 10–
100 ng/ml in cancer cells. ET-743-mediated apoptosis,
did not involve Fas/CD95. ET-743 induced c-Jun NH2-
terminal kinase (JNK) and caspase-3 activation, and
JNK and caspase inhibition prevented ET-743-induced
apoptosis. ET-743 failed to promote apoptosis in
caspase-3-deficient MCF-7 cells, further implicating
caspase-3 in its proapoptotic action. Overexpression of
bcl-2 by gene transfer abrogated ET-743-induced apo-
ptosis, but cells underwent cell cycle arrest. ET-743 trig-
gered cytochrome c release from mitochondria that was
inhibited by Bcl-2 overexpression. Inhibition of tran-
scription or protein synthesis did not prevent ET-743-
induced apoptosis, but abrogated ET-743-induced cell
cycle arrest. Microarray analyses revealed changes in
the expression of a small number of cell cycle-related
genes (p21, GADD45A, cyclin G2, MCM5, and histones)
that suggested their putative involvement in ET-743-in-
duced cell cycle arrest. These data indicate that ET-743 is
a very potent anticancer drug showing dose-dependent
cytostatic and proapoptotic effects through activation of
two different signaling pathways, namely a transcription-
dependent pathway leading to cell cycle arrest and a tran-
scription-independent route leading to rapid apoptosis
that involves mitochondria, JNK, and caspase-3.
Ecteinascidin-743 (ET-743)1 is a marine-derived compound
isolated from the marine tunicate Ecteinascidia turbinata (1,
2), with a potent cytotoxic activity against a variety of tumors
in vitro and in vivo (3–5). The preclinical in vivo experiments
with ET-743 showed cytotoxic activity of the drug when admin-
istered at g/m2 dosages, yielding nanomolar plasma concen-
trations (6, 7). Current phase II clinical trials in Europe and
the United States indicate that ET-743 represents a highly
promising antitumor agent. However, the mechanism by which
ET-743 exerts its anticancer activity remains to be elucidated.
ET-743 has been reported to bind to the minor groove of DNA
(8, 9), bending DNA toward the major groove (10). DNA-bound
ET-743 appeared to modify the interaction between DNA and
several transcription factors (11, 12). Also, at high concentra-
tions ET-743 and the related synthetic drug phthalascidin,
have been reported to target topoisomerase I (13, 14). However,
the relevance of these actions for the antitumor activity of
ET-743 can be questioned as they are evidenced at drug con-
centrations much higher than those required for achieving its
antitumor effect. On the other hand, ET-743-treated cells have
been reported to accumulate in S and G2/M phases (15–18).
To elucidate the mechanism underlying the anticancer effect
of ET-743, we investigated the putative role of apoptosis in
ET-743 action as an explanation for its cytotoxic effect. In this
work we have found evidence for the induction of c-Jun NH2-
terminal kinase (JNK)-, mitochondria-, and caspase-3-medi-
ated apoptosis in human cancer cells by ET-743 in a dose- and
time-dependent way. Also, at very low concentrations, ET-743
is able to inhibit cell proliferation, accumulating cells in S or
G2/M, before promoting apoptosis after prolonged incubations.
Our findings indicate that Bcl-2 overexpression is able to block
the apoptotic effects of ET-743, preserving its actions on cell
cycle. Cell cycle arrest induced by ET-743 was transcription-
dependent, but ET-743-induced apoptosis was independent of
transcription and of Fas/CD95. ET-743 had a rather weak
effect on gene expression, but changes in the expression of a
small number of genes seemed to account for the ET-743-
promoted cell cycle arrest. Thus, ET-743 exerts two major
concentration-dependent effects, namely cytostatic and pro-
apoptotic, when used at concentrations (nM) required for the in
vivo ET-743 anticancer action; therefore, these actions can
account for the antitumor properties of the marine compound.
Our data indicate that ET-743-induced cell cycle arrest and
apoptosis result from the activation of two different signal
transduction pathways.
EXPERIMENTAL PROCEDURES
Reagents—ET-743 was obtained from PharmaMar (Madrid, Spain)
and prepared as a 1 mg/ml stock solution dissolved in ethanol and kept
at 20 °C. Before use, the drug was diluted freshly in double-distilled
sterile water to the desired concentrations. Dulbecco’s modified Eagle’s
medium and RPMI 1640, fetal calf serum, antibiotics, and L-glutamine
were purchased from Invitrogen. Rabbit polyclonal antiserum against
human caspase-3 was from PharMingen (San Diego, CA). Mouse mono-
clonal antibody C2.10 against human poly(ADP-ribose) polymerase
(PARP) was purchased from Enzyme Systems Products (Livermore,
CA). Mouse monoclonal antibody Ab-1 against Bcl-2, and the JNK
inhibitor SP600125 were from Calbiochem (Cambridge, MA). The
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caspase inhibitor z-Asp-2,6-dichlorobenzoyloxymethylketone (z-D-
dbmk) and the recombinant human Fas ligand (FasL) were from Alexis
(La¨ufelfingen, Switzerland). Acrylamide, bisacrylamide, ammonium
persulfate, and N,N,N,N-tetramethylethylenediamine were from Bio-
Rad (Richmond, CA). All other chemicals were from Merck (Darmstadt,
Germany) or Sigma.
Cells and Culture Conditions—The following human leukemic cell
lines were used: the acute myeloid leukemia HL-60 cell line; the T
lymphoid Jurkat cell line, derived from an acute T-cell leukemia pa-
tient; the Bcr-Abl-positive K562 cell line, derived from a chronic my-
elogenous leukemia blast crisis patient; the Fas-resistant T-lymphoid
RAPO leukemic cell line (a kind gift of Dr. P. H. Krammer, German
Cancer Research Center, Heidelberg, Germany); and the erythroleuke-
mia HEL cell line. These cells were grown in RPMI 1640 supplemented
with 10% (v/v) heat-inactivated fetal calf serum, 2 mM L-glutamine, 100
units/ml penicillin, and 24 g/ml gentamicin. The human breast cancer
cell line MCF-7 and the human epithelioid cervix adenocarcinoma HeLa
cell line were grown in Dulbecco’s modified Eagle’s medium supple-
mented with fetal calf serum and antibiotics as above. Cells were
incubated at 37 °C in a humidified atmosphere of 5% CO2 and 95% air.
HEL cells were transfected by electroporation with the SFFV-Neo
expression vector containing the human bcl-2 open reading frame
driven by the long terminal repeat of the splenic focus-forming virus
(pSFFV-bcl-2) as described previously (19) and selected by growth in
the presence of 1 mg/ml G418. As a control, transfection was performed
with empty SFFV-Neo plasmid.
ET-743 was added to the cell cultures at the concentrations and for
the times indicated in the respective figures. Agents used to examine
their action on ET-743-dependent apoptosis were added 20–30 min
before ET-743 treatment. Cell growth was measured by cell counting
and by [3H]thymidine incorporation as described previously (20).
Apoptosis Assays—To assess apoptosis, fragmented DNA was iso-
lated, analyzed by electrophoresis on 1% (w/v) agarose gels, and stained
with ethidium bromide as described previously (20, 21). The induction
of apoptosis was also monitored as the appearance of the sub-G1 peak in
cell cycle analysis (22) using a BD Biosciences FACSCalibur flow cy-
tometer (San Jose, CA). Quantitation of apoptotic cells was calculated
as the percentage of cells in the sub-G1 region (hypodiploidy) in cell
cycle analysis.
The possible implication of Fas/FasL interaction in ET-743-induced
apoptosis was evaluated by using the blocking anti-Fas SM1/23 IgG2b
monoclonal antibody (Bender, Vienna, Austria) as described previously
(23). Experiments performed with mock irrelevant isotype immuno-
globulins had no effect.
Western Blot Analysis—About 107 cells were pelleted by centrifuga-
tion, washed with phosphate-buffered saline, lysed and subjected to
Western blot analysis as described previously (24). Proteins (20 g)
were separated through sodium dodecyl sulfate (SDS)-polyacrylamide
gels under reducing conditions, transferred to nitrocellulose filters,
blocked with 5% powder defatted milk, and incubated overnight with
the corresponding antibodies. Signals were developed using an en-
hanced chemiluminescence (ECL) detection kit (Amersham Bio-
sciences, Aylesbury, UK).
Solid Phase JNK Assay—Protein kinase assays were carried out
using a fusion protein between GST and c-Jun (amino acids 1–223) as
a substrate for JNK, as described previously (22, 25). Cells (3–5  106)
were resuspended in 200 l of extract buffer (25 mM HEPES, pH 7.7, 0.3
M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100, 20 mM
-glycerophosphate, 0.1 mM Na3VO4, 0.5 mM phenylmethylsulfonyl flu-
oride, 1 g/ml leupeptin, 1 g/ml aprotinin). Cells were incubated for 30
min in continuous rotation at 4 °C and then microfuged at 12,000 rpm
for 10 min. Pellets were discarded, and the supernatants, representing
cell extracts, were diluted with 600 l of dilution buffer (20 mM HEPES,
pH 7.7, 0.1 mM EDTA, 2.5 mM MgCl2, 0.05% Triton X-100, 20 mM
-glycerophosphate, 0.1 mM Na3VO4, 0.5 mM phenylmethylsulfonyl flu-
oride, 1 g/ml leupeptin, 1 g/ml aprotinin). Mixtures were incubated
for 10 min on ice and then microfuged at 12,000 rpm for 10 min. The cell
extracts were mixed with 20 l of a suspension in dilution buffer of
glutathione-agarose beads to which GST-c-Jun was freshly bound. Mix-
tures were rotated overnight at 4 °C in an Eppendorf tube and pelleted
by centrifugation at 12,000 rpm for 1 min. After four 1-ml washes in
dilution buffer containing 50 mM NaCl to remove kinases that have a
weaker affinity to bind c-Jun-(1–223) than JNK, the pelleted beads
were resuspended in 30 l of kinase buffer (20 mM HEPES, pH 7.7, 2
mM dithiothreitol, 20 mM -glycerophosphate, 20 mM MgCl2, 0.1 mM
Na3VO4, 20 M ATP) and incubated with 4 Ci of [-
32P]ATP. After 1 h
at 30 °C, the reaction was terminated by washing with dilution buffer
containing 50 mM NaCl and microfugation at 12,000 rpm for 1 min.
Then the beads were boiled with 10 l of 5  SDS-polyacrylamide gel
sample buffer to elute the phosphorylated proteins, which were subse-
quently resolved in a 10% SDS-polyacrylamide gel, followed by autora-
diography. These conditions have been shown to enable specific binding
of JNK to the c-Jun NH2-terminal domain (25).
Cytochrome c Release Measurement—Release of cytochrome c from
mitochondria to cytosol was analyzed by Western blot as previously
described (26). Briefly, cells (4  106) were harvested by centrifugation,
washed once with ice-cold phosphate-buffered saline, and gently lysed
(by pipetting up and down 5 times) for 30 s in 50 l of ice-cold buffer
containing 250 mM sucrose, 1 mM EDTA, 0.05% digitonin, 25 mM Tris,
pH 6.8, 1 mM dithiothreitol, 1 g/ml leupeptin, 1 g/ml pepstatin, 1
g/ml aprotinin, 1 mM benzimidine, and 0.1 mM phenylmethylsulfonyl
fluoride. Lysates were centrifuged at 12,000  g at 4 °C for 2 min to
obtain the supernatants (cytosolic extracts free of mitochondria) and
the pellets (fraction that contains mitochondria). Supernatants (40 g
of protein) and pellets (40 g of protein) were electrophoresed on 15%
SDS-polyacrylamide gels and analyzed by Western blot using anti-
cytochrome c antibody (7H8.2C12, from PharMingen) and cytochrome c
oxidase subunit II antibody (12C4-F12, from Molecular Probes, Eugene,
OR) and ECL.
Affymetrix Microarray Analysis—Total RNA was isolated using a
RNeasy kit (Qiagen, Valencia, CA). RNA integrity was assessed with an
AGILENT 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Ger-
many) using a RNA Nano LabChip (Agilent Technologies). Double-
stranded cDNA was synthesized from 15 g of total RNA by means of
the SuperScriptTM double-stranded cDNA synthesis kit (Invitrogen,
San Diego, CA) with oligo(dT)24 primer containing T7 RNA polymerase
promoter. In vitro transcription was carried out by means of the Bioar-
ray High Yield RNA Transcript Labeling kit (Enzo Diagnostics,
Farmingdale, NY) with biotinylated cytidine triphosphate and uridine
triphosphate. The biotin-labeled complementary RNA (cRNA) was
purified with an RNeasy column and fragmented at 94 °C for 35 min in
fragmentation buffer (40 mM Tris acetate, pH 8.1, 100 mM potassium
acetate, 30 mM magnesium acetate). Integrity of cDNA, cRNA, and
fragmented cRNA was assessed by electrophoresis of the samples on 1%
agarose gels.
Microarray RNA analysis was performed according to the manufac-
turer’s protocol using the Human Genome U95Av2 GeneChip (Af-
fymetrix), which represents 12,625 human genes. Scanned output files
were visually inspected for hybridization artifacts and then analyzed
with the Affymetrix Microarray Suite 5.0 software. Arrays were scaled
to an average intensity of 100 and analyzed independently. Genes were
considered up-regulated or down-regulated if the expression was
changed at least two-fold from the control. Only reliable and consistent
mean values from four independent experiments with an appropriate
standard deviation were considered. Data with low signal intensity,
high background, and high variability among experiments were
eliminated.
Statistical Analyses—Unless otherwise indicated, the results given
are the mean ( S.D.) of the number of experiments indicated.
RESULTS
Dose-response and Time Course Effects of ET-743 on HL-60
and HeLa Cells—Human acute myeloid leukemia HL-60 cells
were incubated with ET-743 for different periods of time at
concentrations ranging from 0.1–100 ng/ml (0.131–131 nM, ET-
743 mol. wt. is 761) and analyzed by flow cytometry (Figs. 1 and
2). No significant effect on cell cycle was observed at doses of
0.1 ng/ml ET-743. Incubation with 1 ng/ml ET-743 resulted in
accumulation of cells in G2/M (Figs. 1 and 2) and blockade of
cell proliferation (98% inhibition after 24 h treatment) (data
not shown). About 50% of the cells were arrested at G2/M with
4n content of DNA after 24-hour incubation (Figs. 1 and 2).
This G2/M arrest eventually led to cell death as protracted
incubations with 1 ng/ml ET-743 induced a weak apoptotic
response (about 11% apoptosis after 72 h of treatment).
Treatment of HL-60 cells with 10 or 100 ng/ml ET-743 resulted
in the rapid appearance of cells with a DNA content less than
G1, characteristic of apoptotic cells (Figs. 1 and 2), with no
previous changes in cell cycle (Fig. 1, and data not shown).
Similar results were obtained when human cervix carcinoma
HeLa cells were incubated with ET-743 (Fig. 3). Incubation
with 1 ng/ml ET-743 resulted first in an increase of cells in S
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phase and then in accumulation of cells in G2/M (Fig. 3), with
a blockade of cell proliferation (100% inhibition after 24 h
treatment) (data not shown). No apoptotic response was elic-
ited by 1 ng/ml ET-743 after 48 h treatment (Fig. 3). The effect
on cell cycle was not reversed after drug washout, and cells
eventually underwent apoptosis (about 12%, after 72 h of
ET-743 washout). Incubation of HeLa cells with 10 (Fig. 3) or
100 (data not shown) ng/ml ET-743 resulted in a time-depend-
ent accumulation of apoptotic cells with no previous changes in
cell cycle.
Internucleosomal DNA Degradation Induced by ET-743—To
demonstrate that ET-743 was able to induce an apoptotic
response, we analyzed DNA degradation in ET-743-treated
HL-60 and HeLa cells. Fig. 4 shows that ET-743, at concentra-
tions of 10 or 100 ng/ml, induced the typical internucleosomal
DNA fragmentation in multiples of 180–200 bp, a hallmark for
apoptosis, in both tumor cell types.
Fas/CD95 Does Not Participate in ET-743-induced Apo-
ptosis—Involvement of the Fas/CD95 receptor/ligand system
has been proposed to mediate apoptosis induced by several
anticancer drugs (27). The implication of Fas/FasL interaction
in ET-743-induced apoptosis in the human acute T-cell leuke-
mia Jurkat cells was evaluated by using the blocking anti-Fas
SM1/23 monoclonal antibody, which abrogates Fas/FasL-medi-
ated killing. Preincubation with SM1/23 anti-Fas antibody to-
FIG. 1. Time course of the effects of ET-743 on HL-60 cell cycle distribution. HL-60 cells were untreated or treated with 1 or 10 ng/ml
ET-743 for the times indicated, and their DNA content was analyzed by fluorescence flow cytometry. The position of the sub-G1 peak (hypodiploidy),
integrated by apoptotic cells, as well as the G0/G1 and G2/M peaks are indicated by arrows. The experiment was repeated four times and
representative histograms are shown.
FIG. 2. Dose response of the ET-743-induced effect on cell cycle
in HL-60 cells. Cells were incubated with increasing concentrations of
ET-743 for 24 h, and the proportion of cells in each phase of the cell
cycle was quantitated by flow cytometry. Cells in the sub-G1 region
represent apoptotic cells. Untreated control cells were run in parallel.
Data are shown as means of four independent experiments  S.D.
FIG. 3. Time course of the effect of ET-743 on HeLa cell cycle
distribution. HeLa cells were incubated with 1 or 10 ng/ml ET-743 for
the indicated times, and the proportion of cells in each phase of the cell
cycle was quantitated by flow cytometry. Cells in the sub-G1 region
represent apoptotic cells. Untreated control cells were run in parallel.
Data are shown as means of four independent experiments  S.D.
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tally prevented apoptosis induced by the agonistic cytotoxic CH
11 anti-Fas monoclonal antibody in Jurkat cells, but had no
protective effect on ET-743-induced apoptosis (Fig. 5), suggest-
ing that Fas/FasL interactions are not required for ET-743-
induced apoptosis. We also found that ET-743 induced apo-
ptosis in the Fas-resistant T-lymphoid RAPO leukemic cells
(42.1  4.3% and 76.8  6.3% apoptosis after 24 h treatment
with 10 and 100 ng/ml ET-743, respectively, n 3). RAPO cells
express Fas (about 60% cells positive for Fas), but incubation
with 50 ng/ml CH 11 antibody or 50 ng/ml recombinant human
FasL for 24 h did not induce apoptosis (less than 2.5% apo-
ptosis, n  3), indicating that Fas was non-functional in these
cells. Furthermore, ET-743 induced apoptosis in the Fas-neg-
ative K562 leukemic cells (23), namely 19.2% and 25.3% apo-
ptosis after 24 h treatment with 10 and 100 ng/ml ET-743,
respectively. These results indicate that ET-743-induced apo-
ptosis does not involve Fas/CD95.
ET-743-induced Apoptosis Is Mediated by Persistent JNK
Activation—Because JNK activation has been suggested to be
involved in the induction of apoptosis by different insults (28,
29), we examined whether ET-743 was able to activate JNK in
HeLa and HL-60 cells through phosphorylation of its substrate
c-Jun. To determine JNK activation, we used a GST fusion
protein containing amino acids 1–223 of c-Jun (GST-c-Jun) as a
substrate for JNK. ET-743 (10 and 100 ng/ml) induced a per-
sistent JNK activation, measured as phosphorylation of GST-
c-Jun, before the onset of apoptosis (Fig. 6). When ET-743 was
used at 1 ng/ml, no JNK activation was detected before cell
cycle arrest (data not shown). Curcumin (diferuloylmethane),
an inhibitor of the JNK signaling pathway (30), inhibited both
ET-743-induced JNK activation and apoptosis (Fig. 7, A and B).
Furthermore, pretreatment of cells with the novel JNK inhib-
itor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) (31) inhibited
both ET-743-induced JNK activation and apoptosis (Fig. 7, C
and D). These results suggest that the JNK signaling pathway
is involved in ET-743-induced apoptosis.
Involvement of Caspase-3 Activation in ET-743-induced
Apoptosis—We found that ET-743 induced caspase-3 activation
in HL-60 and HeLa cells as assessed by cleavage of procaspase-3
into the p17 active form and cleavage of the typical caspase-3
substrate PARP, using a polyclonal anti-human caspase-3 anti-
body that recognized the 32-kDa proenzyme (pro-caspase-3)
and the 17-kDa form of the active caspase-3, and the anti-
PARP C2.10 monoclonal antibody that detected both the 116-
kDa intact form and the 85-kDa cleaved form of PARP (Fig.
8A). The caspase-3 cleavage product p19 observed in Fig. 8A
represents the p17 subunit plus the short caspase-3 prodomain,
which is then slowly converted into the active p17 subunit (32).
Incubation with the aspartate-based caspase inhibitor z-Asp-
2,6-dichlorobenzoyloxymethylketone (z-D-dbmk) completely
blocked PARP degradation (data not shown) and apoptosis in
ET-743-treated HL-60 cells (Fig. 8B) and HeLa cells (data not
shown). We also found that MCF-7 cells, which are deficient in
caspase-3 because of a 47-bp deletion within exon 3 of the
caspase-3 gene (33), did not undergo apoptosis upon ET-743
treatment (4.1  1.4% apoptosis in untreated MCF-7 cells
versus 4.2  1.7% apoptosis in MCF-7 cells treated with either
10 or 100 ng/ml ET-743 for 24 h, n 3). These data support the
involvement of caspase-3 in ET-743-induced apoptosis.
Inhibition of ET-743-induced Apoptosis by Overexpression of
bcl-2—Bcl-2 regulates apoptosis, acting as suppressor (34).
Thus, we analyzed whether ET-743-induced apoptosis was un-
der Bcl-2 control in human erythroleukemia HEL cells. These
cells were stably transfected with pSFFV-bcl-2 (HEL-Bcl-2),
containing the human bcl-2 open reading frame, or with control
pSFFV-Neo plasmid (HEL-Neo). Western blot analysis indi-
cated that HEL-Neo cells expressed no Bcl-2, whereas a high
expression of this protein was observed in HEL-Bcl-2 cells, as
previously reported (19, 22). HEL-Neo cells were accumulated
in S phase before undergoing apoptosis when treated with 10
ng/ml ET-743 and underwent apoptosis without any previous
effect on cell cycle at 100 ng/ml ET-743 (Fig. 9A). Overexpres-
sion of Bcl-2 by gene transfer prevented ET-743-induced apo-
ptosis, even after 72 h of treatment. But cells did not proliferate
(100% inhibition in cell growth) and accumulated in S or G0/G1
when treated with 10 or 100 ng/ml ET-743, respectively (Fig.
FIG. 4. Internucleosomal DNA fragmentation induced by ET-
743. HeLa and HL-60 cells were incubated for 24 h with increasing
concentrations of ET-743 and assayed for DNA fragmentation as de-
scribed under “Experimental Procedures.” Untreated control cells were
run in parallel. Fragmented DNA from 6 105 cells were loaded in each
lane of the agarose gel. A 123-bp DNA ladder was used as standard.
Data are representative of three independent experiments performed.
FIG. 5. The Fas/FasL system is not involved in ET-743-induced
apoptosis. The effect of blocking anti-Fas monoclonal antibody on
ET-743-induced apoptosis in T lymphoid leukemic Jurkat cells was
analyzed. Cells were preincubated with blocking SM1/23 antibody for
30 min before addition of cytotoxic anti-Fas CH 11 antibody or 10 ng/ml
ET-743 for 24 h. Untreated control cells and cells incubated only with
SM1/23 antibody, CH 11 antibody, or ET-743 for 24 h were run in
parallel. Apoptosis was then quantitated as a percentage of cells in the
sub-G1 region in cell cycle analysis. Data are shown as the means of
three independent experiments  S.D.
FIG. 6. Time course of ET-743-induced JNK activation in HeLa
and HL-60 cells. Cells were treated with 10 or 100 ng/ml ET-743 for
the times indicated and assayed for JNK activation. Untreated control
cells were run in parallel in the same gel. The position of phosphoryl-
ated GST-c-Jun-1–223 (GST-c-Jun) is indicated. Experiments shown
are representative of three performed.
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9B). Quantitative data showed that 65.0  5.6% and 66.2 
5.0% (n 3) of HEL-Bcl-2 cells treated for 72 h with 10 and 100
ng/ml ET-743 accumulated at S and G0/G1 phase, respectively,
whereas 43.1  3.7% and 38.1  3.1% (n  3) of untreated
HEL-Bcl-2 cells were in G0/G1 and S phase, respectively.
ET-743 Induces Translocation of Mitochondrial Cytochrome
c into the Cytosol—Because ET-743-triggered apoptosis was
tightly controlled by Bcl-2, we asked whether ET-743 could
trigger mitochondrial cytochrome c release, as Bcl-2 has been
reported to interfere with cytochrome c release from mitochon-
dria (34). As shown in Fig. 10, cytosolic cytochrome c levels
markedly and rapidly increased after treatment of HL-60 cells
with proapoptotic concentrations of ET-743 (100 ng/ml). Simi-
lar results were obtained also when cells were treated with 10
ng/ml ET-743 (data not shown). However, no cytochrome c
release was detected when HL-60 cells were incubated with 1
ng/ml ET-743 for up to 12 h of treatment (data not shown),
conditions that did not promote apoptosis. Overexpression of
Bcl-2 in HEL cells prevented both apoptosis (Fig. 9) and mito-
chondrial cytochrome c release (data not shown). These results
suggest that cytochrome c release from mitochondria is an
early event in ET-743-induced apoptosis.
Inhibition of Protein Synthesis Prevents ET-743-induced Cell
Cycle Arrest, but Not ET-743-induced Apoptosis—Because the
cytotoxic activity of ET-743 has been previously related to its
capacity to affect transcription (11, 12), we examined whether
inhibition of macromolecule synthesis could affect the apoptotic
action of ET-743. Pretreatment of HeLa cells with cyclohexi-
mide or actinomycin D, used at concentrations that inhibited
protein and mRNA synthesis (Ref. 35 and data not shown), did
not affect the apoptotic response induced by ET-743, but the
cell cycle arrest following incubation with 1 ng/ml ET-743 was
completely prevented (Fig. 11).
Changes in Gene Expression Induced by ET-743 During Cell
Cycle Arrest—Because the effects of ET-743 on cell cycle arrest
were caused by a transcription-mediated process (Fig. 11), we
investigated the effects of ET-743 on gene expression by
using Affymetrix Human Genome U95Av2 GeneChip oligo-
nucleotide arrays. HeLa cells were treated with 1 ng/ml ET-
743 for 48 h, under conditions that induced G2/M arrest
(69.2  8.6% cells were arrested in G2/M, n  4) but no
apoptosis, and their gene expression pattern was compared with
untreated control HeLa cells. Table I lists 89 genes that were
down- and up-regulated at least two-fold by drug treatment; 20
transcripts were down-regulated and 69 transcripts were up-
regulated. Although the relevance of some of the mRNAs that
were regulated by ET-743 treatment is unclear, we found signif-
icant changes in the expression of a number of cell cycle-related
genes (histones, MCM5, cyclin G2, GADD45A and p21) that could
explain the transcription-mediated effect of ET-743 on cell cycle
arrest (Table I). Histones and MCM5 were down-regulated in
ET-743-treated cells, and histones have been found to play a role
during the G2/M transition (36). Reduced minichromosome main-
tenance (MCM) protein levels induce a delay in S phase and
hamper cell cycle progression (37). ET-743 treatment up-
regulated cyclin G2, GADD45A and p21 transcripts, and cyclin
G2 has been reported to be up-regulated during late S phase (38)
and during growth inhibition (39). GADD45A (40) and p21 (41)
induce G2 cell cycle arrest. Thus, the changes in the expression of
these five cell cycle-related genes could account for the observed
effects of ET-743 on cell cycle, namely a delay in S phase and an
arrest in G2/M phase.
FIG. 7. Effect of curcumin and SP600125 on ET-743-induced JNK activation and apoptosis. HeLa cells were incubated in the absence
or in the presence of curcumin (20 M), ET-743 (100 ng/ml) or curcumin  ET-743 for 8 h and analyzed for JNK activation (A) or for 24 h and
analyzed for apoptosis through fluorescence flow cytometry (B). HL-60 cells were incubated in the absence or in the presence of SP600125 (20 M),
ET-743 (10 ng/ml), or SP600125  ET-743 for 8 h and analyzed for JNK activation (C), or for 24 h and analyzed for apoptosis through fluorescence
flow cytometry (D). The position of phosphorylated GST-c-Jun-1–223 (GST-c-Jun) is indicated. Experiments shown are representative of three
performed.
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DISCUSSION
The data reported here demonstrate that ET-743 is able to
induce an apoptotic response leading to the internucleosomal
DNA degradation in human cancer cells. This apoptotic activity
of ET-743 can account for the previously reported cytotoxic
effects exerted by this antitumor agent (1–5). Takahashi et al.
(42) has recently reported that a combination of doxorubicin
and ET-743 induced a weak apoptotic response, based on nuclei
morphology, in fibrosarcoma cell lines, but no apoptosis was
detected following treatment with ET-743 alone. Here, we show
compelling evidence for the proapoptotic activity of ET-743
itself in different cell lines by using a combination of different
techniques. Our data also demonstrate that the apoptotic effect
of ET-743, leading to internucleosomal DNA degradation, is
independent of transcription and of Fas/CD95 but involves
JNK, mitochondria, and caspase-3. The ability of ET-743 to
rapidly induce cytochrome c release from mitochondria as well
as the abrogation of ET-743-induced apoptosis and mitochon-
drial cytochrome c release by Bcl-2 overexpression indicates a
major role for mitochondria in the induction of apoptosis by this
marine antitumor drug. Both JNK activation and mitochon-
drial cytochrome c release constitute early events in ET-743-
induced apoptosis as they are detected in the first 6 h of
treatment. Furthermore, we found that ET-743 exerts two ma-
jor dose-dependent actions on cancer cells: (a) transcription-
dependent growth arrest with an accumulation of cells in S and
G2/M when used at 1–10 ng/ml, and (b) transcription-indepen-
dent apoptosis when used at 10–100 ng/ml. These data explain
the previous in vitro antiproliferative activity of the compound
assessed by using metabolic assays, leading to the notion that
ET-743 is a potent and effective antiproliferative drug at the
ng/ml (nM, ET-743 mol. wt. is 761) range.
ET-743 has been shown to alkylate DNA, preferentially at
GC-rich sequences (8, 9). Previous reports have shown that
ET-743 inhibits at the M range (10 M) the activity of vari-
ous DNA-binding factors, including TBP, E2F, SRF, and NF-Y
(11). High concentrations (M range) of ET-743 have also been
reported to inhibit topoisomerase I and to induce protein-linked
DNA single-strand breaks (11, 13–15). However, the high con-
centrations required in vitro to detect these effects raise the
question of the pharmacological relevance of such observations,
as ET-743 is cytotoxic and pharmacologically active at much
lower concentrations (nM range). In addition, the relevance of
the action of ET-743 on topoisomerase I is questionable because
this drug is equally active in cells lacking detectable topoi-
somerase I (15). Two recent studies reported that relatively low
concentrations (10–50 nM) inhibited the transcriptional activa-
tion of cellular genes regulated by the NF-Y transcription fac-
tor, including MDR1, and possibly by the Sp1 transcription
factor (12, 43). However, although ET-743 interaction with the
DNA seems to be well characterized (8, 9), the molecular mech-
anisms by which such an interaction leads to growth arrest and
cytotoxicity are not well understood. The data reported here,
showing that pharmacologically relevant concentrations (nM) of
ET-743 induce a potent apoptotic response, indicate that trig-
gering of apoptosis can be the major action in ET-743
cytotoxicity.
We have also found that ET-743 induced an accumulation of
cells in S phase and a G2/M arrest when used at very low doses,
in agreement with previous observations (15–18). It has been
reported that ET-743 disorganizes the microtubule network
(44), but this action was evidenced at very high drug concen-
trations (M). We have not detected any effect of ET-743 on the
microtubule network when pharmacologically active concen-
trations (1–10 ng/ml) of ET-743 were used.2 Interestingly, we
have found here that the action of ET-743 on cell cycle was
dependent on transcription. To investigate the genes responsi-
ble for this transcription-dependent cell cycle inhibition, we
carried out Affymetrix Microarray analyses of the RNA expres-
sion profiles in HeLa cells treated with doses of ET-743 that
induced exclusively cell cycle arrest and no apoptosis, and
compared these array data with those from untreated control
HeLa cells. We calculated mean values from four different
experiments, and only those with an acceptable standard devi-
ation, after stringent analysis, were considered to be consistent
and reliable figures. Although ET-743 has been reported to
influence transcription (11, 12, 43), the number and extension
of changes in gene expression induced by the drug was rather
low. Carrying out parallel experiments of cell cycle and mi-
croarray analyses, we found that only 89 genes of the 12,625
genes analyzed were regulated in their expression (20 down-
regulated genes and 69 up-regulated genes) when cells were
treated under conditions that induced cell cycle arrest (1 ng/ml
ET-743, 48 h). Interestingly, we found that ET-743 regulated
the expression of five cell cycle-related genes that could explain
the transcription-dependent effect of ET-743 on cell cycle,
namely up-regulation of cyclin G2, GADD45A and p21 tran-
scripts, and down-regulation of histones and MCM5. Up- and
down-regulation of the above genes have been reported to in-
duce an increase in S phase and a G2/M arrest in different
systems (36–41), the same effects observed in ET-743-treated
cells. Thus, these data prompt us to envisage a hypothesis
2 F. An, C. Gajate, and F. Mollinedo, unpublished observations.
FIG. 8. Involvement of caspase-3 in ET-743-induced apoptosis.
A, time course of caspase-3 and PARP cleavage in ET-743-treated
HL-60 and HeLa cells. Cells were treated with ET-743 for the indicated
times and analyzed by immunoblotting with anti-caspase-3 and anti-
PARP antibodies. The migration positions of full-length caspase-3 and
the p19 and p17 cleavage products, as well as of full-length PARP and
its cleavage product p85 are indicated. B, caspase inhibition prevents
apoptosis in ET-743-treated cells. HL-60 cells were incubated with 10
ng/ml ET-743 in the absence or in the presence of 50 M z-Asp-2,6-
dichlorobenzoyloxymethylketone (z-D-dbmk) for 24 h, and then ana-
lyzed for DNA degradation by flow cytometry. Untreated control cells
and cells treated only with the caspase inhibitor were also run in
parallel. The percentage of cells with a DNA content less than G1,
representing apoptotic cells, is indicated in each histogram. Data shown
are representative of three experiments performed.
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where changes in the expression of the above genes may lead to
the transcription-dependent cytostatic effects induced by ET-
743. This represents a working hypothesis that must be tested
in future experiments. In addition to the above genes, we also
found that ET-743 regulated the expression of additional genes
FIG. 9. Prevention of ET-743-induced apoptosis by Bcl-2 overexpression. The cell cycle and apoptotic effects of ET-743 on HEL-Neo (A)
and HEL-Bcl-2 (B) cells are shown. The drug concentrations used and the incubation times are indicated. The DNA content of untreated control
cells (upper left histograms in A and B) and cells treated with ET-743 was analyzed by fluorescence flow cytometry. The position of the G0/G1 peak
is indicated by arrows. The percentage of cells with a DNA content less than G1 (sub-G1), representing apoptotic cells, is indicated in each
histogram. Data shown are representative of three experiments performed.
FIG. 10. ET-743 triggers cytosolic accumulation of cytochrome
c. HL-60 cells treated with 100 ng/ml ET-743 were harvested at the
indicated times, and cytosolic and mitochondrial proteins were ana-
lyzed by immunoblotting with anti-cytochrome c (A) or anti-cytochrome
c oxidase II (B). Cytochrome oxidase serves as a marker for mitochon-
drial contamination of cytosolic extracts. A mitochondrial extract from
untreated control cells (Mit. Fr.) was used as a positive control for
cytochrome c and cytochrome oxidase. Data shown are representative of
three experiments performed. FIG. 11. Effect of protein synthesis inhibition on the actions of
ET-743 in cell cycle and apoptosis. HeLa cells were preincubated for
20 min in the absence and in the presence of 500 ng/ml cycloheximide
(CHX) or 50 ng/ml actinomycin D (ActD) and then treated with different
concentrations of ET-743 for 20 h. The proportion of cells in each phase
of the cell cycle was quantitated by flow cytometry. Cells in the sub-G1
region represent apoptotic cells. Untreated control cells were run in
parallel. Data are shown as the means of three independent experi-
ments  S.D.
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TABLE I
Gene expression changes induced by ET-743 in HeLa cells
Genes related to cell cycle are labeled in bold. Data show the fold change values of genes in ET-743-treated HeLa cells compared to untreated
control HeLa cells. Data are shown as mean values  S.D. of four independent experiments. Listed here are genes that showed at least a 2-fold
change in expression.
Accession no.
Fold change
Gene definition Putative function
Mean S.D.
AF042377 6.0 2.9 GDP-mannose 4,6-dehydratase metabolism
AF036715 3.4 0.9 syntaxin 8 membrane traffic
AA255502 3.0 1.3 H4 histone family, member G cell cycle; transcription
AF097441 2.9 0.4 phenylalanine-tRNA synthetase protein biosynthesis
D64142 2.6 0.7 H1 histone family, member X cell cycle; transcription
X81889 2.6 0.8 plakophilin 4 cell adhesion
X60484 2.6 0.8 H4 histone family, member E cell cycle; transcription
X69550 2.5 0.7 Rho GDP dissociation inhibitor (GDI) alpha signal transduction; cell adhesion
AF070598 2.4 0.2 ATP-binding cassette, sub-family B (MDR/TAP), member (ABCB6) drug resistance
Z75330 2.2 0.9 stromal antigen 1 (SA-1) unknown
X74795 2.1 0.3 minichromosome maintenance protein 5 (MCM5) cell cycle; DNA replication
U95006 2.1 0.3 D9 splice variant A unknown
AB020641 2.1 0.6 PFTAIRE protein kinase 1 (PFTK1) signal transduction
U28042 2.0 0.2 DEAD/H box polypeptide 10 (RNA helicase) (DDX10) transcription
AL021154 2.0 0.2 EST unknown
AF096870 2.0 0.2 tripartite motif-containing 16 (TRIM16) transcription
M83822 2.0 0.2 beige-like protein (BGL) membrane traffic
AJ006778 2.0 0.2 down-regulated in metastasis (DRIM) negative control of cell proliferation
AA195301 2.0 0.2 hypothetical protein MGC2574 unknown
U63824 2.0 0.2 TEA domain family member 4 transcription
M82809 2.0 0.2 annexin A4 (ANXA4) membrane traffic
AI951946 2.0 0.2 EST unknown
X74764 2.0 0.2 discoidin domain receptor family, member 2 cell adhesion; signal transduction
M15036 2.0 0.2 protein S (alpha) blood coagulation
L06797 2.0 0.2 chemokine (C-X-C motif), receptor 4 (fusin) cell-cell signaling
AF025887 2.0 0.2 glutathione S-transferase A4 stress response
AI017574 2.0 0.2 cysteine-rich protein 1 cell proliferation
L06845 2.0 0.2 cysteinyl-tRNA synthetase protein biosynthesis
U41843 2.0 0.3 DR1-associated protein 1 (negative cofactor 2 alpha) repression of transcription
U47414 2.0 0.3 cyclin G2 cell cycle checkpoint
V01512 2.0 0.3 c-fos transcription
M77349 2.0 0.3 transforming growth factor, beta-induced, 68 kD cell proliferation
L19182 2.0 0.3 insulin-like growth factor binding protein 7 (IGFBP7) negative control of cell proliferation
M60974 2.0 0.3 growth arrest and DNA-damage-inducible, alpha (GADD45A) cell cycle arrest; DNA repair; apoptosis
U28014 2.0 0.3 caspase-4 apoptosis
D16532 2.0 0.3 very low density lipoprotein receptor metabolism
AL050002 2.0 0.3 DKFZp5640222 unknown
AJ001685 2.0 0.3 NKG2E NK cell regulation
M14058 2.0 0.3 complement component C1r complement; proteolysis
W72186 2.0 0.3 S100 calcium-binding protein A4 membrane traffic
X51405 2.0 0.3 carboxypeptidase E (CPE) signal transduction; metabolism
AA131149 2.0 0.3 S100 calcium-binding protein P membrane traffic
AI382123 2.0 0.5 EST unknown
U15932 2.0 0.5 dual specificity phosphatase 5 heat shock response; signal transduction
X58536 2.0 0.5 major histocompatibility complex, class I, C immune response regulation
M84526 2.0 0.5 D component of complement (adipsin) complement; proteolysis
L00972 2.0 0.5 Human cystathionine-beta-synthase metabolism
U51334 2.0 0.5 TAF15 RNA polymerase II transcription
AI535653 2.0 0.5 sterol-C4-methyl oxidase-like (SC4MOL) metabolism
M25915 2.0 0.5 clusterin metabolism
U09510 2.0 0.5 glycyl-tRNA synthetase protein biosynthesis
AL096717 2.0 0.5 DKFZp564P0662 unknown
AF023462 2.1 0.2 phytanoyl-CoA hydroxylase metabolism
M59040 2.1 0.3 CD44 antigen metastasis; homing
D50918 2.1 0.3 septin 6 signal transduction
L13463 2.1 0.3 regulator of G-protein signaling 2, 24kD signal transduction
U60521 2.1 0.3 caspase-9 apoptosis
U57646 2.1 0.3 cysteine and glycine-rich protein 2 development; differentiation; cytoskeleton
X17042 2.1 0.3 proteoglycan 1, secretory granule extracellular matrix
AB020662 2.1 0.3 golgin-67 (KIAA0855) Golgi-targeted protein
D49950 2.1 0.3 interleukin 18 (IL18) cell-cell signaling
D31885 2.1 0.4 ADP-ribosylation factor-like 6 interacting protein (KIAA0069) unknown
AL080061 2.1 0.5 DKFZp56H182 unknown
AF000381 2.1 0.5 folate binding protein metabolism
X76732 2.1 0.5 nucleobindin 2 DNA binding
D86425 2.1 0.7 nidogen 2 (NID2) cell adhesion
U03106 2.2 0.2 cyclin-dependent kinase inhibitor 1A (p21, Cip1) cell cycle arrest
AI445461 2.2 0.3 transmembrane 4 superfamily member 1 (TM4SF1) cell proliferation
X13589 2.2 0.3 cytochrome P450 drug metabolism
AI885381 2.2 0.5 hypothetical protein MGC2650 unknown
D50840 2.2 0.5 UDP-glucose ceramide glucosyltransferase metabolism
U40490 2.3 0.3 nicotinamide nucleotide transhydrogenase energy pathways
X76534 2.3 0.3 glycoprotein (transmembrane) nmb negative control of cell proliferation
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involved in cell proliferation and induced expression of prolif-
eration repressors (Table I) that could also be involved in the
transcription-dependent inhibition of cell cycle by ET-743.
Martinez et al. (17) have recently reported an array-based gene
expression study analyzing about 5,000 genes in breast carci-
noma MDA-MB-435 cells and colon carcinoma HCT116 cells
treated with 2 nM ET-743 for 12 h, showing that down-regula-
tion of transcripts was predominant over the up-regulation of
transcripts, with 54–61 down-regulated genes and 1–8 up-
regulated genes. In agreement with our data, up-regulation of
p21 by ET-743 was consistently found in that study in both cell
types. In addition we have found that at shorter drug incuba-
tion times (1 ng/ml ET-743, 24 h) ET-743 had a very weak effect
on gene expression, considering mRNA levels modified in at
least two-fold, and the predominant effect was down-regulation
(25 down-regulated genes versus 3 up-regulated genes).3 Al-
though some similarities can be found between the array data
reported by Martinez et al. (17) and our present microarray
profiles, including the relatively low number of genes regulated
by the drug, differences are also evident. These differences can
be caused by the use of distinct cell lines (HeLa versus HCT116
and MDA-MB-435 cells), different experimental conditions (1
ng/ml–1.3 nM ET-743, 48 h versus 2 nM ET-743, 12 h), different
arrays (Affymetrix HGU95Av2 versus HuGeneFL arrays), and
different software to analyze the data. Concerning this last
aspect, we have used the novel Affymetrix Microarray Suite 5.0
software that largely improves the reliability and consistency
of the figures at the expense of a significant decrease in the fold
change values obtained with previous software versions.
Fig. 12 depicts a scheme of the different effects exerted by
ET-743 on cell cycle and apoptosis based on the present results.
ET-743 inhibits cell proliferation at 1–10 ng/ml, leading to an
accumulation of cells in the S or G2/M phases after 24–48 h of
treatment. ET-743 promotes apoptosis after 6–17 h of treat-
ment at 10–100 ng/ml without any previous effect on cell cycle.
Overexpression of Bcl-2 inhibited apoptosis induced by ET-743,
but cells underwent cell cycle arrest and were unable to prolif-
erate, suggesting that Bcl-2 blocks ET-743-induced apoptotic
signaling but preserves the drug effects on cell cycle. Depend-
ing on the ET-743 dose used, overexpression of Bcl-2 in HEL
cells arrested cells in S or G0/G1. Thus, ET-743 seems to be able
to affect different cell cycle checkpoints in a dose-dependent
way. Although the ET-743 antitumor action has previously
been related to its effects on transcription (11, 12, 43), the lack
of effect of actinomycin D and cycloheximide on ET-743-in-
duced apoptosis indicates that ET-743 can induce cell death
through a transcription-independent route.
The data reported here indicate that the apoptotic pathway
triggered by 10–100 ng/ml ET-743 involves mitochondrial cy-
tochrome c release, JNK activation, and caspase-3 activation.
However, further studies must be completed to establish a
hierarchy in their actions; therefore, the order of appearance of
these three signaling routes in the model outlined in Fig. 12
does not necessarily indicate the actual sequence of cause-effect
events or hierarchical order in the apoptotic signaling induced
by ET-743. Recent reports suggest that JNK activation pre-
cedes mitochondrial cytochrome c release (45, 46). However, we
have found that inhibition of JNK activation by either curcu-
min (30) or by the novel JNK inhibitor SP600125 (31) inhibited
apoptosis, but potentiated cytochrome c release from mitochon-3 F. Mollinedo, and C. Gajate, unpublished observations.
TABLE I—continued
Accession no.
Fold change
Gene definition Putative function
Mean S.D.
X04430 2.3 0.3 interleukin 6 (IL6) signal transduction
X05908 2.3 0.3 annexin A1 (ANXA1) membrane traffic
M59465 2.3 0.3 tumor necrosis factor, alpha-induced protein 3 (TNFAIP3) unknown
X04412 2.4 0.2 gelsolin actin modification
L19871 2.4 0.2 activating transcription factor 3 (ATF3) transcription
W47047 2.4 0.3 p8 protein (candidate of metastasis 1) metastasis
AJ225089 2.4 0.3 2-5-oligoadenylate synthetase-like metabolism
U78793 2.5 0.3 folate receptor alpha metabolism
X92720 2.5 0.8 phosphoenolpyruvate carboxykinase 2 metabolism
S73591 2.7 0.8 thioredoxin interacting protein unknown
M31452 2.9 0.4 complement component 4-binding protein, alpha (C4BPA) complement; cell recognition
M13755 3.2 0.8 interferon-stimulated protein, 15 kDa unknown
AJ011497 3.4 0.4 claudin 7 cell-cell communication
M27396 3.5 0.5 asparagine synthetase metabolism
AI989422 4.4 0.7 fibrinogen, gamma polypeptide metastasis; cell adhesion
X01703 5.0 0.9 tubulin, alpha 3 cytoskeleton
FIG. 12. Anti-proliferative and proapoptotic actions of ET-743
on tumor cells. This is a schematic diagram designed to portray the
biological processes and biochemical events that we have detected in
human cancer cells treated with different concentrations of ET-743. At
low concentrations, ET-743 affects mainly cell cycle, leading to cell
growth inhibition and eventually to late apoptosis after very prolonged
incubation times. At higher concentrations ET-743 induces an early
apoptotic response without any previous effect on cell cycle. Timings for
the different processes elicited by ET-743 are shown in boxes. Overex-
pression of Bcl-2 inhibits mitochondrial cytochrome c release and pre-
vents cells from entering into apoptosis, but cells undergo cell cycle
arrest. Prevention of JNK or caspase activation also inhibits apoptosis.
The hierarchical order of mitochondrial cytochrome c release, JNK
activation, and caspase-3 activation remains to be established. There-
fore, the order of appearance of these signaling events in the figure does
not necessarily indicate the actual sequence of cause-effect events in the
apoptotic signaling induced by ET-743.
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dria in ET-743-treated cells,4 suggesting that JNK activation
could occur downstream of mitochondrial cytochrome c release.
This is in agreement with recent reports indicating that cur-
cumin, an agent that has been reported to exert both pro- or
anti-apoptotic actions (47–54), potentiates mitochondrial cyto-
chrome c release (49, 53) and can even induce opening of the
mitochondrial permeability transition pore (55). Nevertheless,
curcumin, a dietary yellow pigment from Curcuma longa, has
been reported to affect a great variety of signaling processes in
different systems (47–54), and these pleiotropic effects pre-
clude to reach a clear picture of the hierarchical events occur-
ring in curcumin-pretreated cells.
The distinct actions on cell cycle and apoptosis induced by
ET-743 suggest that this drug is able to trigger different signal
transduction pathways and indicate that ET-743 is able to
exert effects on two key processes in cancer treatment, namely
cell cycle and apoptosis. Taken together, our data demonstrate
the high capacity of ET-743 to stop proliferation and to trigger
apoptosis in human cancer cells at very low and pharmacolog-
ically relevant doses (ng/ml, nM). Therefore, ET-743 is a prom-
ising anticancer drug that can be useful in the treatment of
different cancers with either high or low proliferation rates.
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